Trial Profile
A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms ARISE-3
- Sponsors G-treeBNT; ReGenTree
- 02 May 2022 Status changed from active, no longer recruiting to completed.
- 02 Mar 2022 According to a ReGenTree Media Release, the pre-BLA (Biologics License Application) meeting was held by the Office of New Drugs/Office of Specialty Medicine in CDER and the Department of Ophthalmology/Office of Specialty Medicine, including specialists from statistics, safety, pharmacology, CMC, GCP and RA at FDA on 28 Feb 2022 to discuss a potential BLA submission for RGN-259 for dry eye syndrome.
- 15 Sep 2021 Planned End Date changed from 30 Apr 2021 to 30 Dec 2021.